Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab for High-risk Transplant-associated Thrombotic Microangiopathy
NCT07707687Phase 2Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jul 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
A Phase 2 trial of eculizumab in transplant-associated thrombotic microangiopathy (TA-TMA), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Started Jul 2026; status: recruiting.
02
Drugs
eculizumab
03
Conditions
transplant-associated thrombotic microangiopathy (TA-TMA)
Beyond the preview
Go deeper on NCT07707687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07707687.